Vectura Group PLC said a U.K. court voted in favor of GlaxoSmithKline PLC relating to a dispute on an agreement between the two companies.

The litigation pertains to certain additional patents under an August 2010 patent license and option agreement with GlaxoSmithKline.

U.K.-based Vectura said it was evaluating a future course of action, including an option to appeal, with its advisers.

Vectura expects the results of the U.K. lawsuits will not materially affect its other cases pending against GlaxoSmithKline in the U.S.

Vectura, which develops and markets products for airways-related diseases, had signed an agreement with Hikma Pharmaceuticals PLC in November to develop and commercialize generic versions of GlaxoSmithKline's Ellipta portfolio of respiratory therapies.